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A B S T R A C T
Background: Alzheimer’s disease (AD)-related pathology is frequently found in patients with dementia with
Lewy bodies (DLB). However, it is unknown how amyloid-β and tau-related pathologies influence neurode-
generation in DLB. Understanding the mechanisms underlying brain atrophy in DLB can improve our knowledge
about disease progression, differential diagnosis, drug development and testing of anti-amyloid and anti-tau
therapies in DLB.
Objectives: We aimed at investigating the combined effect of CSF amyloid-β42, phosphorylated tau and total tau
on regional brain atrophy in DLB in the European DLB (E-DLB) cohort.
Methods: 86 probable DLB patients from the E-DLB cohort with CSF and MRI data were included. Random forest
was used to analyze the association of CSF biomarkers (predictors) with visual rating scales for medial temporal
lobe atrophy (MTA), posterior atrophy (PA) and global cortical atrophy scale-frontal subscale (GCA-F) (out-
comes), including age, sex, education and disease duration as extra predictors.
Results: DLB patients with abnormal MTA scores had abnormal CSF Aβ42, shorter disease duration and older
age. DLB patients with abnormal PA scores had abnormal levels of CSF Aβ42 and p-tau, older age, lower edu-
cation and shorter disease duration. Abnormal GCA-F scores were associated with lower education, male sex, and
older age, but not with any AD-related CSF biomarker.
Conclusions: This study shows preliminary data on the potential combined effect of amyloid-β and tau-related
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pathologies on the integrity of posterior brain cortices in DLB patients, whereas only amyloid-β seems to be
related to MTA. Future availability of α-synuclein biomarkers will help us to understand the effect of α-synuclein
and AD-related pathologies on brain integrity in DLB.
1. Introduction
Neuropathological studies have shown that many patients diag-
nosed with dementia with Lewy bodies (DLB) often have Alzheimer’s
disease (AD)-related pathology (Gomez-Isla et al., 1999; Schneider
et al., 2009; Halliday et al., 2011; Dugger et al., 2014; Sierra et al.,
2016) In these mixed cases, it has been found that the degree of AD-
related pathology is moderate or severe in more than 70% of patients
(Kosaka, 1990; Marui et al., 2004; Barker et al., 2002; Irwin et al.,
2017). The combination of these proteinopathies have implications in
the clinical phenotype. Thus, postmortem studies have shown that the
coexistence of amyloid-β and tau-related pathologies in addition to the
defining alpha-synuclein pathology usually results in a less typical
presentation of DLB core features: a lower frequency of recurrent visual
hallucinations, parkinsonism, REM sleep behavior disorder (RBD) and
fluctuating cognition (Merdes et al., 2003; Del Ser et al., 2001;
Tiraboschi et al., 2015; Compta et al., 2013; Murray et al., 2013), and a
more severe disease course (Irwin et al., 2017; Howlett et al., 2015;
Kraybill et al., 2005; Williams et al., 2006).
Similar findings have been obtained in vivo (Di Censo et al., 2020),
which is more relevant for the earlier disease stages compared to the
end-stage diseases assessed at autopsy. In this regard, cerebrospinal
fluid (CSF) and neuroimaging studies have shown concomitant AD-re-
lated biomarkers in a significant proportion of DLB patients who often
are older, have shorter disease duration and worse cognitive perfor-
mance (Van Steenoven et al., 2016; Gomperts et al., 2016; Abdelnour
et al., 2016; Lemstra et al., 2017), mainly in orientation and memory
(Andersson et al., 2011; Tagawa et al., 2015).
Nevertheless, how AD-related pathology influences the neurode-
generative process in DLB is less studied. In AD, amyloid-β and tau-
related pathologies are hypothesized to lead to neuronal injury (Hyman
et al., 2012; Braak et al., 2006). DLB patients with concomitant AD-
related pathology have shown a faster rate of brain atrophy over time
measured with MRI, mainly in the medial temporal lobe, when com-
pared with DLB patients without concomitant AD-related pathology
(Nedelska et al., 2015; Sarro et al., 2016; Blanc et al., 2017; Nelson
et al., 2009). This finding suggests that AD pathology may contribute to
medial temporal lobe atrophy (MTA) in DLB (Elder et al., 2017; Sarro
et al., 2016). Similarly, when amyloid is present the patterns of de-
position and atrophy resembles that observed in AD (Shimada et al.,
2013; Donaghy et al., 2015; Irwin and Hurtig, 2018; Mak et al.,
2019ab) Understanding the underlying mechanisms of regional brain
atrophy that could reflect distinct pathologies could have treatment
implications. For example, a typical AD pattern of brain atrophy in-
volving the medial temporal lobes and posterior cortices was associated
with poorer response to acetylcholinesterase inhibitors in DLB patients
(Graff-Radford et al., 2012). Also, amyloid or tau-targeted therapies
might be effective in a subgroup of patients with DLB, i.e. it is im-
portant to improve our understanding in what degree AD pathologies
may contribute towards personalized medicine approaches and im-
prove differential diagnosis, disease prognosis, and treatment response
in DLB.
Combining CSF biomarkers and structural MRI may inform about
the mechanisms underlying regional atrophy, but few studies have been
performed in DLB and results are inconsistent. A recent study reported
an association between abnormal levels of CSF Aβ42 and MTA in DLB,
as well as an association between abnormal levels of CSF total tau (T-
tau) and global brain atrophy (van der Zande et al., 2018). By contrast,
another study reported no differences between amyloid PET positive
and negative DLB patients in hippocampal or gray matter volume
(Donaghy et al., 2018). However, associations between regional
atrophy and tau-related pathology have not been investigated yet. Im-
portantly, in vitro studies have found cross-seeding of alpha-synuclein,
amyloid and tau proteins (Spires-Jones et al., 2017), thus the combi-
nation of proteinopathies may have additional or even synergistic
contributions to neurodegeneration. Hence, we aimed to explore this
question by investigating the combined effect of CSF Aβ42, T-tau and p-
tau on regional brain atrophy in the E-DLB cohort, a large multi-center
study involving 19 centers from Europe (Oppedal et al., 2019). Our
hypothesis was that DLB patients with abnormal levels of CSF Aβ42, T-
tau and p-tau would have a higher level of brain atrophy, in particular,
in the medial temporal lobes and posterior cortices, delineating the
typical pattern of brain atrophy in AD (Oppedal et al., 2019).
2. Materials and methods
2.1. Participants population
A total of 86 DLB patients were selected from 6 centers of the E-DLB
cohort. Inclusion criteria to enter the E-DLB cohort are reported in
previous publications (Kramberger et al., 2017). For the current study,
selection criteria were: 1) a diagnosis of probable DLB; 2) availability of
CSF data; and 3) availability of MRI data. Detailed information about
the centers that contributed to the current study is shown in
Supplementary tables.
2.2. Diagnostic and clinical examination
Because the E-DLB cohort was assembled retrospectively, many
patients had been diagnosed before 2017. Hence, The DLB diagnosis
was made according to McKeith 2005 criteria (McKeith et al., 2005),
but we were able to confirm the diagnosis of probable DLB according to
McKeith 2017 criteria (McKeith et al., 2017) in 83 out of 86 patients.
Diagnosis was made by the treating physician, a group of at least two
expert clinicians, or a multidisciplinary team at a consensus diagnostic
meeting on the basis of all available clinical and diagnostic test data as
previously reported (Oppedal et al., 2019; Kramberger et al., 2017).
Clinicians interviewed both patients and caregivers, recorded de-
mographic information as well as medical and drug history. All centers
included a detailed medical history, aside from physical, neurological,
and psychiatric examinations using standardized scales such as the
motor subscale of the Unified Parkinson’s Disease rating scale (Fahn
et al., 1987) and the Neuropsychiatric Inventory (Cummings et al.,
1994). Based on the clinical examination and/or the aforementioned
scales the core diagnostic features fluctuating cognition, parkinsonism,
and recurrent visual hallucinations were recorded as present or absent.
Neuropsychological evaluation and complementary tests to rule out
secondary causes of dementia (routine blood tests and brain imaging)
were performed. 26 out of the total sample of 86 subjects had available
DAT SPECT, 25 (96.15%) of which were abnormal.
2.3. Ethics
Local ethics committees at the individual centres approved the
study. The patients gave their written consent to use the anonymised
results of their clinical, instrumental and laboratory investigations for
research purposes.
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2.4. CSF procedures
CSF was obtained at all centers with the following procedures: 1)
lumbar puncture at the L3-4 or L4-5 interspace; 2) collection in poly-
propylene tubes and centrifuged for 10 min at 4 °C; and 3) storage in
aliquots of 0.5 mL at −80 °C or −70 °C until further analysis. Further
details are summarized in Supplementary Table 1. CSF analyses were
performed locally according to standard routines. INNOTEST enzyme-
linked immunosorbent assays (ELISA) were used to analyze T-tau and p-
tau (missing for 1 patient) in all samples and Aβ42 in 80 samples
(Fujirebio, Ghent, Belgium). The remaining 6 samples were analyzed
for Aβ42 using ELISA kits from Biosource Europe S.A. CSF values were
dichotomized as normal or pathological based on well-established
center-specific cut-off values for each biomarker as previously de-
scribed (Abdelnour et al., 2016) (Supplementary Table A.1).
2.5. MRI analysis
Different neuroimaging acquisition protocols and MRI scanners
were used as detailed in Supplementary Table A.2. The interval be-
tween MRI and CSF collection ranged from 0 to 3 months in the ma-
jority of the cases (73 out 86, which corresponds to 84.88%). In 13
patients the interval ranged from 3 to 12 moths (15.12%). We used
visual rating of MRI scans, which is more feasible for clinical use than
automated analysis, and is not influenced by between-center differences
in acquisition protocols and MRI scanners. Ratings of all scans were
performed by one expert radiologist (L. C.) as previously described
(Ferreira et al., 2017), who has excellent intra-rater reliability -
weighted κ of 0.94 and 0.89 for MTA in left and right hemispheres
correspondingly, 0.88 for PA, and 0.83 for GCA-F in 120 random cases-
(Ferreira et al., 2017) blinded to clinical data. T1-weigthed images were
used to investigate regional brain atrophy by using three visual rating
scales: the medial temporal lobe atrophy scale (MTA) (Scheltens et al.,
1992), the posterior atrophy scale (PA) (Koedam et al., 2011) and the
global cortical atrophy scale-frontal subscale (GCA-F) (Ferreira et al.,
2016). Detailed information regarding the visual rating scales is pro-
vided elsewhere (Ferreira et al., 2017). The visual rating scores were
dichotomized into normal and abnormal values in accordance with
previously proposed cut-offs (Ferreira et al., 2015)
2.6. Statistics
The statistical analyses were done using R (www.R-project.org)
version 3.2.4 and IBM SPSS version 26. Descriptive results are shown as
mean ± SD for normally distributed continuous variables, and number
and percentage for categorical variables.
The aim of this study was to investigate the combined effect of
Aβ42, T-tau and p-tau (predictors) on regional brain atrophy as mea-
sured with visual rating scales (outcome variables). All these measures
are dichotomous (0 normal, 1 abnormal). We also wanted to model the
effects of age, sex, education and disease duration to investigate their
possible added effect to the association between CSF biomarkers and
regional brain atrophy. Age, education and disease duration are con-
tinuous variables while sex is dichotomous (0 males 1 females). Further,
our interest was to investigate the predictive power of all these vari-
ables in combination as predictors of regional brain atrophy, rather
than investigating their partial effects. Random forest (classification)
(Breiman, 2001) was thus chosen given our aim, the nature of the
variables, the number of predictors and the sample size. Random forest
is an ensemble method in machine learning that involves growing of
multiple decision trees via bootstrap aggregation (bagging). Each tree
predicts a classification independently and votes for the corresponding
class. The best model for each outcome variable is chosen from the
majority of votes (Machado et al., 2018). Importantly, contrarily to
other predictive methods such as multiple linear or logistic regression
that investigate partial effects (competition among predictors in the
prediction of the outcome), random forest investigates combined effects
(the predictors do not compete with each other but “cooperate” in the
prediction of the outcome) (Machado et al., 2018) Combined effects are
closer to what we hypothesized in this study, i.e., amyloid-β (CSF Aβ42)
and tau-related (CSF p-tau) pathologies have a synergistic deleterious
effect on brain integrity. When CSF Aβ42 and CSF p-tau as predictors
show a contribution to the prediction of brain atrophy, we can conclude
that both pathologies have a combined effect on brain integrity, which
may reflect their synergy at the pathological level (i.e. the “coopera-
tion” between Aβ42 and CSF p-tau contributes to the prediction of brain
atrophy). Further, random forest performs very similarly to other ma-
chine learning algorithms (Machado et al., 2018) but it was preferred in
our current study due to the nature of our variables. We performed
three random forest models: one for each atrophy scale (MTA, PA, and
GCA-F) as the outcome variable. The random forest models were
comprised of 5000 trees, providing an accurate estimation of the vari-
ables importance without introducing too much noise in the models due
to the addition of redundant trees. Each of the trees was trained on
randomly picked 70% of the data and subsequently tested on the un-
seen 30% of the data. Classification models (normal vs. abnormal)
(Liaw and Wiener, 2002) were conducted, accounting for the fact that
the outcome variable may present with an unbalanced amount of cases
in its two levels (e.g. normal MTA n = 53, abnormal MTA n = 34). The
classification error is reported as a measure of goodness of the model
(out-of-the-bag estimated error rate, OOB-EER) (Breiman, 2001). When
outcome variables are dichotomous, as it is our case, the error by
chance is 50%. Therefore, a classification below 50% is better than
chance, with values closest to 0% denoting better classification per-
formance, hence good reliability of the model. We also report the im-
portance (Imp) of the predictors as a measure of their contribution to-
wards the prediction of the outcome variable (regional brain atrophy).
Higher Imp values denote stronger contribution to the prediction. The
random forest results were further complemented with the Pearson
correlation coefficient to easily represent the magnitude and direction
of the association between variables (bivariate association). P-values of
Pearson correlation are reported for completeness of information.
3. Results
3.1. Sample features
Clinical and demographic features of the sample are reported in
Table 1. Of the 86 patients, the number of patients with pathological
CSF values is 28 (32.56%) for Aβ42, 17 (19.77%) for Total-Tau and 24
(27.91%) for p-Tau. The number of patients with abnormal scores in the
visual rating scales was: MTA: 33 (38.37%), GCA-F: 34 (39.53%) and
PA: 45 (52.33%). Fig. 1 shows 3 examples of different combinations for
CSF Aβ42, CSF p-Tau CSF and the visual rating scales.
Table 1
Demographic and clinical data of the participants.
Features Mean (SD) Range
Age at diagnosis 69.36 (8.85) 49–88
Sex: Male N (%) 49 (56.98)
Years of education 11.24 (4.08) 5–22
Disease duration (years) 4.04 (3.10) 0.5–14
MMSE 24.85 (3.72) 15–30
Parkinsonism (%) 82.6 (N = 71)
Visual hallucinations (%) 58.1 (N = 50)
Fluctuating cognition (%) 75.6 (N = 65)
N: number. MMSE: Minimental State Examination.
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3.2. Association between AD CSF biomarkers and visual rating scores
measured with MRI
The distribution of abnormal scores in the visual rating scales in
relation to normal or pathological CSF Aβ42, T-tau and p-tau is pre-
sented in Table 2.
Classification performance in the three random forest models was
better than chance: MTA, OOB-EER = 32.56%; PA, OOB-
EER = 44.83%, GCA-F, OOB-EER = 24.14% (Table 3). The classifi-
cation error for normal MTA was 24.52% and for abnormal MTA it was
45.45%. The classification error for normal PA was 46.34% and for
abnormal PA it was 43.48%. The classification error for normal GCA-F
Fig. 1. Normal and pathological CSF values of Aβ42 and p-Tau combined with visual rating scales. CSF levels of Aβ42 and p-Tau were dichotomized according the
cut-offs of each center into normal or pathological values. MTA, PA and GCA-F visual rating scales were used to measure regional atrophy based on T1-weigthed
images. A+= pathological CSF Aβ42; A− = normal CSF Aβ42; T+= pathological CSF p-Tau; T− = normal CSF p-Tau; MTA = medial temporal atrophy scale;
PA = posterior atrophy scale; GCA-F = global cortical atrophy scale – frontal subscale; A = anterior part of the brain; P = posterior part of the brain; R = right;
L = left.
Table 2
Distribution of abnormal visual rating scores between normal and pathological AD CSF biomarkers groups.
CSF Aβ42 CSF T-tau CSF p-tau
Visual rating scales Normal Abnormal Normal Abnormal Normal Abnormal
Abnormal MTA N (%) 18 (54.55) 15 (45.45) 28 (84.85) 5 (15.15) 26 (78.79) 7 (21.21)
Age (mean and SD) 69.78 (8.37) 73.93 (6.68) 70.86 (8.01) 76.20 (5.07) 70.27 (8.13) 76.86 (3.34)
Sex (Male N and %) 11 (61.11) 6 (40) 18 (64.29) 2 (40) 17 (65.38) 3 (42.86)
Disease duration (mean and SD) 3.64 (2.91) 2.43 (2.35) 3.11 (2.80) 3.00 (2.35) 2.87 (2.54) 3.93 (3.32)
Abnormal PA N (%) 25 (55.56) 20 (44.44) 33 (73.33) 12 (26.67) 29 (64.44) 16 (35.56)
Age (mean and SD) 67.24 (9.40) 75.70 (6.78) 70.24 (8.22) 73.08 (11.88) 69.17 (8.07) 74.31 (10.62)
Sex (Male N and %) 15 (60) 12 (60) 20 (60.61) 7 (58.33) 18 (62.07) 9 (56.25)
Disease duration (mean and SD) 3.98 (2.69) 2.48 (1.57) 3.26 (2.24) 3.46 (2.78) 2.91 (1.91) 4.03 (2.96)
Abnormal GCA-F N (%) 19 (55.88) 15 (44.12) 27 (79.41) 7 (20.59) 20 (58.82) 14 (41.18)
Age (mean and SD) 70.68 (9) 75.93 (7.06) 71.30 (8.57) 79.57 (6.05) 70.95 (8.57) 75.93 (8.36)
Sex (Male N and %) 14 (73.68) 11 (73.33) 20 (74.07) 5 (71.43) 15 (75) 10 (71.43)
Disease duration (mean and SD) 4.61 (3.08) 2.77 (2.15) 3.63 (2.74) 4.43 (3.31) 3.18 (2.20) 4.68 (3.44)
N: number. CSF: cerebrospinal fluid. Aβ42: Amyloid-β42. T tau: Total tau. P tau: phosphorylated tau at threonine 181. MTA: medial temporal lobe atrophy. PA:
posterior atrophy. GCA-F: global cortical atrophy scale-frontal subscale.
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scores was 19.23% while it was 31.43% for patients with abnormal
values. Table 3 shows that the best predictors of MTA were disease
duration, CSF Aβ42 and age, ordered by importance. We found a
combined effect of CSF Aβ42 and CSF p-tau on PA. Age, education and
disease duration also contributed to the prediction of PA. Finally, the
best predictors of GCA-F were sex, education and age. AD CSF bio-
markers did not contribute to the prediction of GCA-F. The same pat-
tern of results was observed when adding the center as a predictor in
the models (data not shown), thus suggesting that variability across-
centers does not seem to affect our findings.
Pearson correlation coefficients show that abnormal scores in MTA
were related to abnormal CSF Aβ42 levels, whereas abnormal values of
PA were associated with both abnormal CSF Aβ42 and p-tau levels.
Regarding the effect of age, sex, education and disease duration, ab-
normal scores in MTA were related to shorter disease duration and
older age. Abnormal scores in PA were related to older age, less edu-
cation and shorter disease duration. Abnormal scores in GCA-F were
related to less education, male sex and older age (Table 3). Fig. 2 shows
the correlation matrix between visual ratings and CSF biomarkers, as
well as among all predictors in our random forest models (Breiman,
2001).
4. Discussion
We found that both amyloid-β and tau-related pathologies con-
tribute in combination to atrophy in posterior brain cortex of probable
DLB patients. In addition, amyloid β-related pathology was associated
with atrophy in the medial temporal lobe. In contrast, atrophy in the
frontal cortex was not associated with AD-related pathology, and no
associations were found between regional brain atrophy and global
unspecific neurodegeneration (CSF T-tau).
Our results are consistent with previous findings on the association
between amyloid β-related pathology and atrophy in the medial tem-
poral lobe in DLB (Sarro et al., 2016; van der Zande et al., 2018;
Shimada et al., 2013; Mak et al., 2019b; Kantarci et al., 2012a, 2012b).
Although MTA is less frequent in DLB when compared with AD
(Shimada et al., 2013; Barber et al. Mar, 2000; Ballmaier et al., 2004),
previous studies suggest that when MTA is present, it could reflect
concomitant AD-related pathology (Sarro et al., 2016; van der Zande
et al., 2018). Both MTA and abnormal CSF Aβ42 levels are associated
with more rapid cognitive decline in DLB and Parkinson’s disease
(Howlett et al., 2015; Siderowf et al., 2010; Stav et al., 2016; Caspell-
Garcia et al., 2017). An interesting result of our study s that the clas-
sification error was higher for the prediction of patients with abnormal
MTA scores as compared with the prediction of patients with normal
MTA scores. This suggests that while in the absence of amyloid-beta
pathology is unlikely to find MTA in probable DLB, the presence of MTA
is not always associated with amyloid-beta pathology. Other factors
than pathological CSF levels of Aβ42 may be involved in MTA in DLB.
Our study shows that older age and shorter disease duration are asso-
ciated with abnormal MTA scores. Future studies should also consider
other pathologies potentially contributing to MTA, such as TDP-43 or
hippocampal sclerosis.
Furthermore, we found that posterior brain atrophy was associated
with both amyloid-β and tau-related pathologies. We acknowledge
however that this finding should be considered as preliminary given the
high classification error in our model (still under the threshold of error
by chance). PET biomarkers are needed to confirm the collocation of
amyloid and tau-related pathologies and neurodegeneration in the
posterior cortex in DLB. Sarro et al showed that amyloid-β deposition is
associated with greater atrophy rates in the posterior cingulate gyrus
Table 3







MTA Overall model: OOB-EER = 32.56%
‐ Classification error normal
MTA = 24.53%
‐ Classification error abnormal
MTA = 45.45%
Predictors retained in the model:
Disease duration, Imp = 63.53
CSF Aβ42, Imp = 41.71







PA Overall model: OOB-EER = 44.83%
‐ Classification error normal
PA = 46.34%
‐ Classification error abnormal
PA = 43.48%
Predictors retained in the model:
Age, Imp = 24.27
Education, Imp = 8.76
CSF p-tau, Imp = 8.23
CSF Aβ42, Imp = 8.615











GCA-F Overall model: OOB-EER = 24.14%
‐ Classification error normal
GCA-F = 19.23%
‐ Classification error abnormal
GCA-F = 31.43%
Predictors retained in the model:
Sex, Imp = 54.20
Education, Imp = 52.18







N: number. CSF: cerebrospinal fluid. Aβ42: Amyloid-β42. T tau: Total tau. P tau:
phosphorylated tau at threonine 181. MTA: medial temporal lobe atrophy. PA:
posterior atrophy. GCA-F: global cortical atrophy scale-frontal subscale.
OOB-EER: out-of-the-bag estimated error rate (below 50% denotes good clas-
sification performance). Imp: importance (the contribution of a given variable
in the random forest, with higher values indicating stronger contribution to the
prediction). Pearson correlation indicates the direction of the association.
Fig. 2. Correlation matrix between visual ratings, CSF biomarkers, and pre-
dictors in the random forest models. Asterisk symbols (*) denote p-values <
0.05. MTA = medial temporal atrophy scale; PA = posterior atrophy scale;
GCA-F = global cortical atrophy scale – frontal subscale.
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and the occipital lobe in addition to the temporal lobe (Sarro et al.,
2016). Investigation of tau-related pathology with 18F-AV-1451 have
found that DLB patients display increased uptake in the posterior and
inferior temporoparietal, occipital (Kantarci et al., 2017) and parietal
lobes (Smith et al., 2018). These findings indicate that tau-related pa-
thology in DLB does not seem to follow AD Braak neurofibrillary tangle
(NFT) distribution with the typical involvement of the medial temporal
lobe (Braak and Braak, 1991), whereas amyloidosis presents with a
diffuse cortical pattern similar to AD (Coughlin et al., 2019). Hence, the
coexistence of DLB and AD pathologies could result in a distinctive
pattern of regional brain atrophy in DLB. The novelty of our study is
that we show that both amyloid-β and tau-related pathologies seem to
be associated with level of atrophy in posterior cortex, while solely
amyloid-β pathology appears to be related to atrophy in medial tem-
poral lobes. This could be explained by a potential link between amy-
loid-β and tau-related pathologies in posterior brain areas, where tau
pathology is primarily deposited in DLB (Kantarci et al., 2017).
Although both CSF T-tau and brain atrophy are considered markers
of neurodegeneration, we did not find any association between the two.
A possible explanation is that CSF T-tau is a marker of global unspecific
neurodegeneration, while visual rating scales are markers of regional
(local) neurodegeneration. AD studies show that the agreement be-
tween CSF T-tau and brain atrophy is limited (Alexopoulos et al., 2014).
Moreover, we cannot exclude that this negative result is also explained
by the small number of subjects with abnormal levels of CSF T-tau in
our sample. Prior studies also observed that abnormal levels of CSF T-
tau are less frequent than abnormal levels of CSF Aβ42 and p-tau in DLB
patients (Mukaetova-Ladinska et al., 2010). Nevertheless, only one
previous study analyzed CSF T-tau levels and regional brain atrophy in
DLB, finding a correlation with posterior and global brain atrophy (van
der Zande et al., 2018). Therefore, more studies are needed to de-
termine the possible association between CSF T-tau -currently con-
sidered as a biomarker of neuronal damage- and brain atrophy in Lewy
body dementia.
Similarly to what previously reported in AD, neither CSF Aβ42, T-
tau nor p-tau were associated with atrophy in the frontal cortex in DLB
(Ferreira et al., 2016). Previous research has demonstrated increased
amyloid-β burden (Growdon et al., 2012) but not tau deposition
(Kantarci et al., 2017) in frontal areas in patients with DLB. However,
amyloid-β deposition in the frontal lobes has not been associated with
grey matter atrophy in this region (Sarro et al., 2016). Frontal atrophy
in DLB might be related to Lewy body pathology only, but more in-
vestigations are needed to elucidate the pathological mechanisms un-
derlying the neurodegeneration of these areas.
Regarding the effect of age, sex, education and disease duration, we
did not control for their effects but investigated to what extent they
contribute to regional brain atrophy together with the CSF biomarkers.
The decision to do so is because it is currently unknown whether these
variables should be treated as confounding or contributing variables to
regional brain atrophy in neurodegenerative disorders (Ferreira et al.,
2020). For example, tau-related pathology is associated with increasing
age, and it is currently unknown whether tau deposition in DLB is re-
lated to AD- or aging-, or both. Thus, including age, sex, education and
disease duration in our models enabled us to investigate their combined
effect together with the CSF biomarkers. We found that atrophy in
medial temporal lobes and posterior cortices was associated with
shorter disease duration and older age, whereas atrophy in the frontal
cortex was associated with older age, male sex and less education.
Further, our multivariate analyses exposed the effect of variables such
as disease duration on the integrity of the brain, which traditional bi-
variate correlations could not capture in our study. In fact, multivariate
models can capture effects of relevant variables masked by the effect of
third variables that cannot be captured in univariate or bivariate
models, and that are artificially removed in models testing for partial
effects (Machado et al., 2018). This is therefore a strength of our
multivariate statistical approach using random forest classification
models. Another interesting finding is that the Pearson correlation be-
tween CSF p-tau and PA was not significant while CSF p-tau contributed
to the prediction of PA in the multivariate random forest model. This
suggests that the effect of tau-related pathology on the posterior cortex
is not direct and instead emerges in combination with the effect of
amyloid-β pathology. Hence, this dissociation between the results from
our random forest and correlation analysis supports the potential sy-
nergistic effect of amyloid-β and tau-related pathologies when it comes
to predict brain atrophy in the posterior cortex. Since age, education
and disease duration were contributing variables in the random forest
for PA, this suggests that AD-concomitant pathology in DLB may have a
stronger impact on the posterior cortex in patients with lower education
and older age, hence perhaps accelerating disease progression (i.e.
shorter disease duration).
This study has some limitations. Firstly, we discuss on the observed
association between CSF biomarkers and regional brain atrophy but our
analyses are cross-sectional and we cannot assume causality. Still, we
believe our findings may inform on potential underlying mechanisms of
neurodegeneration in DLB, which need to be substantiated in future
longitudinal studies. Secondly, the E-DLB cohort was assembled retro-
spectively using common registered variables and procedures across the
participating centers. However, all variables and procedures are stan-
dard for clinical practice across centers and we carefully inspected the
combinability of the data in order to exclude non-harmonized measures
and cases. All centers have extensive clinical experience in the diagnosis
of neurodegenerative diseases and align with international consensus
diagnostic criteria, which we believe has contributed to minimize po-
tential differences among centers. Further, we followed two more
strategies to minimize methodological differences across-centers. We
used cut-offs that were established at their respective center to di-
chotomize CSF biomarker results into normal or abnormal values,
which is preferred in multi-center studies instead of continuous values.
Similarly, due to the variability in the MRI protocols across centers, we
used visual rating scales to investigate brain atrophy instead of more
fine-grained automated methods or quantitative measures. Nonetheless,
the use of visual rating scales substantially increases the clinical ap-
plicability of our current findings (Ferreira et al., 2017, 2015, 2020).
On another hand, and connected to the retrospective nature of the co-
hort, it is worth mentioning that the interval between MRI and CSF
collection was long in 15.11% of cases (ranged from 3 to 12 moths).
Thirdly, there is no reliable in vivo biomarker of Lewy body pathology
at present for diagnosis or analysis of the contribution of this pathology
towards the neurodegenerative process. Thus, the diagnosis of probable
DLB was based on clinical grounds with its known limitations (Rizzo
et al., 2018; Huang and Halliday, 2013), although around one third of
the cohort had a dopamine transporter SPECT scan. These limitations
will be overcome in the prospective stage of E-DLB – we are currently
collecting harmonized longitudinal data across many centers in Europe
(Oppedal et al., 2019). Finally, although random forest is able to handle
multicollinearity to some degree, it might lead to an underestimation of
the contribution of multicollinear variables. The association among the
predictors of the random forest models can be appreciated in Fig. 2. Our
study has some important strengths. The study is a multicenter effort,
which makes the generalization of the findings plausible through dif-
ferent clinical centers. Also, the use of modern multivariate models
allowed us to investigate the combined effect of CSF biomarkers for the
first time, in contrast to previous reports which investigated partial
effects and could not investigate CSF p-tau in linear regression models
due to collinearity (van der Zande et al., 2018).
5. Conclusions
This study shows preliminary data on the potential combined effect
of amyloid-β and tau-related pathologies on posterior brain cortices in
patients with DLB. Future research should confirm our current findings
with more fine-grained automated methods for brain atrophy and,
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ideally, with amyloid and tau PET biomarkers in order to verify the
potential collocation of these pathologies with neurodegeneration in
posterior brain cortices. Likewise, future studies should also include
alpha-synuclein biomarkers when available in order to advance our
current understanding of the neurodegeneration process in DLB.
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